.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ESTIMABL2 randomized trial evaluated whether patients with low-risk differentiated thyroid cancer could safely avoid routine postoperative radioactive iodine after thyroid surgery. The study found that a no-radioiodine strategy was non-inferior for the primary disease-control endpoint in appropriately selected low-risk patients. This is an important example of treatment de-escalation in endocrine oncology: once a cancer has been completely or appropriately resected and classified as low risk, additional ablation is not automatically required for every patient. For endocrine surgeons, the practical implication is that postoperative management should be based on individualized recurrence risk rather than a one-size-fits-all protocol. Decisions must integrate pathology, surgical completeness, staging, thyroglobulin monitoring and the planned follow-up pathway. Avoiding unnecessary radioactive iodine can reduce treatment burden and prevent potential adverse effects while preserving excellent disease control in selected patients. The trial therefore strengthens a more conservative, risk-adapted approach to differentiated thyroid cancer care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ESTIMABL2 randomized trial evaluated whether patients with low-risk differentiated thyroid cancer could safely avoid routine postoperative radioactive iodine after thyroid surgery. The study found that a no-radioiodine strategy was non-inferior for the primary disease-control endpoint in appropriately selected low-risk patients. This is an important example of treatment de-escalation in endocrine oncology: once a cancer has been completely or appropriately resected and classified as low risk, additional ablation is not automatically required for every patient. For endocrine surgeons, the practical implication is that postoperative management should be based on individualized recurrence risk rather than a one-size-fits-all protocol. Decisions must integrate pathology, surgical completeness, staging, thyroglobulin monitoring and the planned follow-up pathway. Avoiding unnecessary radioactive iodine can reduce treatment burden and prevent potential adverse effects while preserving excellent disease control in selected patients. The trial therefore strengthens a more conservative, risk-adapted approach to differentiated thyroid cancer care.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
